Oriental Ocean's wholly-owned subsidiary, Avioq Bio-Tech, has recently obtained a medical device registration certificate for a neutrophil gelatinase-associated lipocalin assay kit. The product uses a magnetic particle chemiluminescence method for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin levels in human serum. The registration is valid from July 23, 2026, to July 22, 2031. This certification will enrich the company's product line in the clinical testing field, though the product has not yet entered production. In the first quarter of 2026, Oriental Ocean achieved revenue of 78.37 million yuan and a net loss attributable to the parent company of 11.27 million yuan.
Shandong Oriental Ocean Sci-Tech Co LtdSubsidiary obtained medical device registration certificate for a new assay kit, enriching product line.
Avioq Bio-Tech obtained the registration certificate for the neutrophil gelatinase-associated lipocalin assay kit.